Meta-analysis showed that lower APOA1 was associated with unfavorable cancer-specific survival and shorter DFS in overall cancer, inferior total time to recurrence in hepatocellular carcinoma, poorer locoregional RFS, and distant metastasis-free survival in nasopharyngeal carcinoma [47]. Here, APOA1 is linked to cancer.